about
How a β-D-glucoside side chain enhances binding affinity to thrombin of inhibitors bearing 2-chlorothiophene as P1 moiety: crystallography, fragment deconstruction study, and evaluation of antithrombotic propertiesCoagulopathy of Acute Sepsis.Sepsis, thrombosis and organ dysfunction.Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.Monocytes, but not endothelial cells, downregulate the anticoagulant activity of activated protein C.Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.Antithrombotic activity of 12 table grape varieties. Relationship with polyphenolic profile.Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood.Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.Co-administration of low molecular weight heparin enhances the profibrinolytic effect of warfarin through different mechanisms.Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential.Ochratoxin A inhibits the production of tissue factor and plasminogen activator inhibitor-2 by human blood mononuclear cells: another potential mechanism of immune-suppression.A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression.Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis.Thrombolysis enhancing activity of a low molecular weight dermatan sulfate (Desmin 370) in experimental pulmonary embolism in rats.Skin extracts from 2 Italian table grapes (Italia and Palieri) inhibit tissue factor expression by human blood mononuclear cells.Grape intake reduces thrombin generation and enhances plasma fibrinolysis. Potential role of circulating procoagulant microparticles.The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.Role of leucocyte procoagulant activity in endotoxin-induced DIC: evidence from comparative studies in rats and rabbits.Tissue factor and vascular endothelial growth factor expression in colorectal cancer: relation with cancer recurrence.Failure of warfarin to affect the tissue factor activity and the metastatic potential of murine fibrosarcoma cellsEarly increase of a new platelet coagulant activity in rats fed a thrombogenic dietReduced Fibrinolytic Activity in Glomeruli Isolated from Rabbits Infused with Tumor Necrosis FactorEvidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic stateHEREDITARY DYSFUNCTIONAL PROTEIN C (PROTEIN C BERGAMO) AND THROMBOSISStroke in two young siblings with congenital dysfibrinogenemiaWarfarin inhibits both procoagulant activity and metastatic capacity of Lewis Lung Carcinoma cellsCancer cell procoagulant: A novel vitamin K-dependent activityCancer cell procoagulant activity: Evaluation by an amidolytic assayReduced procoagulant activity of Lewis lung carcinoma cells from mice treated with warfarinUrine estrogen profiles in European countries with high or low breast cancer ratesChanges in coagulation-fibrinolysis balance in blood mononuclear cells and in gastric mucosa from patients with Helicobacter pylori infection
P50
Q27695670-F855A5E1-E97B-44B1-8084-21D74C8D37E9Q33425399-46F35D8B-304E-4805-9C31-1909D6B42811Q37953591-89F463C7-3833-4EBB-B518-A97A6DB70FC8Q37960315-021278D8-7D71-4B07-BD04-5DD477700574Q40041367-A44B6979-1AB4-4570-9F38-33E3FFAC4EAFQ40828865-3C6C64A8-0F82-4944-84B0-A82A4072BBBEQ42522659-1048DD47-DF3F-4A47-8529-E5E98E28C4B4Q42588928-06563186-1976-4FE9-B849-FA3ED6C5A5CFQ43120462-2FE033E0-AA9B-4A13-82CC-DF796A93D9C3Q43188577-9214A845-D3A7-4F87-BA56-F4C67A225382Q43653843-07647E67-035A-44F4-9F03-7B79675CF646Q44311743-77E07230-B53B-4320-B584-BEAD9F711AA6Q45395838-2716A776-9075-48D8-B68B-186529D7CA88Q45842157-8F8E9E75-3F49-4A7E-A4F2-B5DFC60B5BDCQ45856680-15C10FD3-11C7-4C93-8450-63316A89CE66Q45861624-7F0E4759-B8BB-4628-96B3-F1A1C8B2F115Q45885169-EB4DF7B8-4AB4-4850-ADA3-0601350B073FQ46485433-4871FE47-6709-4DC8-9DC9-AD0165C28FEDQ46741892-BE2B6775-5AF6-4E6C-8935-8A2963ABA683Q46767665-4FB45D15-736E-4A66-8027-10FDD5462863Q47219115-25442C0C-8241-4060-A2FF-C239ED4A823AQ47301125-0FF16DA5-1069-47D1-8BAC-46323A42DD35Q47306397-30F6EE76-72DD-42D8-B072-F981E4310548Q50081225-4E346F28-672E-4E20-AD80-452D045C355CQ51731993-376E940A-2894-47B8-9144-F924A8879DE5Q53086246-088B93D2-5D2C-454F-B7F6-CE1297B04970Q54527254-41411BC3-3714-473E-AC45-32B18198C201Q54562247-37735885-CDF6-41EE-A2BA-5302A47A92D2Q56943819-891C2287-243B-4FEC-BD43-09DE893ECB6FQ57399022-B0F109B7-F1F7-48D3-A908-8F432E3C0FADQ57704458-5B539A95-2AA8-4273-8D4B-9E2036761068Q57985048-AEF63F76-5010-43B4-B1E8-D1DFF4958323Q59697551-7DE8280A-B889-4C2B-AAF5-21C25D726DF8Q59697652-ACF3D4E0-4713-4AA1-9F99-3991FED0931DQ59697670-CAF96AA1-EA9E-4E7E-BA2D-BC92ABA85980Q59697700-1BE4097E-442F-4721-8325-ECA14C519F11Q59697772-D9B89069-2F60-467C-8160-A44C1FCAEA1AQ59697935-08554B54-C2BE-445D-9BCC-7AF91A2B874DQ59697951-226DB03A-A988-4D15-ACF2-9A2EF0A2B5ABQ62804821-B468EF44-4099-4B99-89A1-3F7EE781F76F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mario Colucci
@ast
Mario Colucci
@en
Mario Colucci
@es
Mario Colucci
@nl
Mario Colucci
@sl
type
label
Mario Colucci
@ast
Mario Colucci
@en
Mario Colucci
@es
Mario Colucci
@nl
Mario Colucci
@sl
prefLabel
Mario Colucci
@ast
Mario Colucci
@en
Mario Colucci
@es
Mario Colucci
@nl
Mario Colucci
@sl
P106
P1153
7005657706
P21
P31
P496
0000-0001-9146-8095